LitCovid-sentences  

PMC:7029759 / 9688-11523 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T59 0-112 Sentence denotes Beyond targeting the surface proteins of 2019-nCoV, one could also target the RNA genome itself for degradation.
T60 113-376 Sentence denotes This RNA genome sequence of 2019-nCoV was recently published (GenBank: MN908947.3), and one strategy that could be considered then, is the use of small interfering RNA (siRNA) or antisense oligonucleotides (ASO) to combat the virus by targeting its RNA genome 23.
T61 377-424 Sentence denotes The challenge with this strategy is multi-fold.
T62 425-493 Sentence denotes First, the conserved RNA sequence domains of CoV-2019 are not known.
T63 494-631 Sentence denotes Identifying conserved sequences is essential in order to optimize siRNA targeting and avoid viral escape of the oligonucleotide strategy.
T64 632-770 Sentence denotes One could look at genome homology of 2019-nCoV to the SARS virus for comparison of conserved sequences, but this would still be guesswork.
T65 771-852 Sentence denotes A second challenge is how the oligonucleotides would be delivered into the lungs.
T66 853-977 Sentence denotes Advances have been made into delivery vehicles such as lipid nanoparticles that can mediate some delivery into the lungs 24.
T67 978-1143 Sentence denotes It is unknown, however, if enough siRNA’s or ASO’s would be effectively delivered within the lungs to stop the infection or make a difference in its clinical course.
T68 1144-1360 Sentence denotes For example, if 25% of alveolar epithelial cells in the lung had siRNA or ASO in them, that efficiency might be a great success for traditional gene therapy, but would hardly make any difference in a viral infection.
T69 1361-1516 Sentence denotes Such an explanation is also likely why siRNA candidates against Ebola failed in trials 25, despite significant success in preclinical animal models 26, 27.
T70 1517-1681 Sentence denotes Lastly, even if one assumed that siRNA was effective clinically, there is a limited ability to scale up manufacturing of siRNA drugs to a large infected population.
T71 1682-1835 Sentence denotes Current siRNA and ASO therapies are manufactured for rare diseases, and there are no available resources existing to manufacture the medications quickly.